AbbVie
ABBV NYSE· Biotechnology
Last close · Oct 26, 2026
$286.74
KIRA · Stoqly’s AI analyst, in plain words
- AbbVie had $61.2B of revenue in fiscal 2025, up 8.6% on the year before. Over five years, revenue changed +6.0% a year on average.
- Its operating margin was 24.7%, up 8.4 pts: of every 100 in sales, about 25 is left after running the business.
- AbbVie made $4.2B of net profit in fiscal 2025. From fiscal 2016 to 2025, diluted EPS grew −4.7% a year.
- Free cash flow was $17.8B in fiscal 2025, 29.1% of revenue.
- AbbVie returned $12.6B to shareholders in fiscal 2025, 71% of free cash flow. The diluted share count rose 0.0%.
- AbbVie owes $61.8B more than it holds in cash, about 2.7 years of operating profit.
Market cap
$507.8B
P/E
81.0x
Revenue
$61.2B
Net income
$4.2B
Free cash flow
$17.8B
Operating margin
24.7%
AbbVie in 30 seconds · fiscal 2025
Are sales growing?
+8.6%
Yes. Sales grew 8.6% last year.
Does it make a profit?
6.9%
A little. It keeps 6.9% of every sale as profit.
Does profit turn into cash?
29.1%
Yes. 29.1% of sales ends up as free cash.
Is debt under control?
2.7x
Keep an eye on it. Repaying its debt would take 2.7 years of operating profit.
How healthy are the accounts?
7 / 9
Solid. It passes 7 of 9 health tests.
How is the share priced?
81.0x
One share costs 81.0 times its yearly profit per share. Typical for its sector: 27.9x.
What AbbVie does
AbbVie researches, makes and sells prescription medicines and related products worldwide. Its main areas are immunology (Skyrizi, Rinvoq and Humira, used for autoimmune diseases), neuroscience (including Vraylar, Botox Therapeutic, and migraine and Parkinson's treatments), oncology (blood cancers and other cancers), and aesthetics (Botox Cosmetic and Juvederm). It also sells eye care products and treatments for hepatitis C and digestive conditions. AbbVie reports as a single business segment. It makes money by selling its medicines. In the United States it sells mainly to three wholesale distributors, McKesson, Cardinal Health and Cencora. No single wholesaler accounted for more than 43% of its 2025 gross revenues in the United States. Outside the United States it sells to wholesalers and distributors and to government payers. Some aesthetic products are sold directly to doctors and other licensed providers.
Biggest risks, in its own words
- Losing patent protection on major products, and the competition from generics and biosimilars that follows.
- Research and development that may not produce new products that can be sold successfully.
- Pricing pressure from governments, rebate programs, and pharmacy benefit managers that influence access to its drugs.
- Safety or effectiveness problems with its products, and product liability claims.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 20, 2026
- Legal name
- AbbVie Inc.
- CIK
- 0001551152
AbbVie · ABBV
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $56.2B | $58.1B | $54.3B | $56.3B | $61.2B |
| Revenue growth | 22.7% | 3.3% | −6.4% | 3.7% | 8.6% |
| Gross margin | 69.0% | 70.0% | 62.4% | 70.0% | 70.2% |
| Operating margin | 31.9% | 31.2% | 23.5% | 16.2% | 24.7% |
| Net income | $11.5B | $11.8B | $4.9B | $4.3B | $4.2B |
| Net margin | 20.5% | 20.4% | 9.0% | 7.6% | 6.9% |
| Diluted EPS | $6.45 | $6.63 | $2.72 | $2.39 | $2.36 |
| Cash | |||||
| Cash from operations | $22.8B | $24.9B | $22.8B | $18.8B | $19.0B |
| Capital expenditure | $787M | $695M | $777M | $974M | $1.2B |
| Free cash flow | $22.0B | $24.2B | $22.1B | $17.8B | $17.8B |
| FCF margin | 39.1% | 41.8% | 40.6% | 31.7% | 29.1% |
| Dividends paid | $9.3B | $10.0B | $10.5B | $11.0B | $11.7B |
| Share buybacks | $934M | $1.5B | $2.0B | $1.7B | $980M |
| Share count change | 6.2% | 0.1% | −0.3% | 0.0% | 0.0% |
| Debt and strength | |||||
| Cash and short-term investments | $9.8B | $9.2B | $12.8B | $5.6B | $5.3B |
| Debt incl. finance leases | $76.0B | $63.2B | $59.3B | $66.9B | $67.0B |
| Shareholders' equity | $15.4B | $17.3B | $10.4B | $3.3B | −$3.3B |
| Net debt / EBITDA | 2.5x | 2.0x | 2.2x | 3.5x | 2.7x |
| Current ratio | 0.8x | 1.0x | 0.9x | 0.7x | 0.7x |
| Interest coverage | 7.4x | 8.1x | 5.7x | 3.3x | 5.2x |
| Returns and quality | |||||
| Return on capital | 18.6% | 20.8% | 15.5% | 15.0% | 15.7% |
| Return on equity | 81.0% | 72.5% | 35.2% | 62.5% | — |
| Piotroski F-score | 6 | 8 | 5 | 6 | 7 |
| Altman Z'' | 0.7 | 1.1 | 0.5 | −0.4 | −0.3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$18.9M
3 insiders
Of sales under plans
50%
$9.5M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
AbbVie · ABBV
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Similar companies
Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score |
|---|---|---|---|---|---|---|---|
| AbbVie ABBV | $507.8B | 8.6% | 24.7% | 29.1% | 15.7% | 81.0x | 7 |
| Johnson & Johnson JNJ | $652.1B | 6.1% | — | 20.9% | 28.6% | 40.4x | 4 |
| Pfizer PFE | $169.8B | −1.7% | — | 14.5% | 7.3% | 39.2x | 6 |
| Moderna MRNA | $79.1B | −39.9% | −158.1% | −106.2% | −65.4% | — | 2 |
Price compared with profit (P/E)
How many times its yearly profit per share one share costs. Higher means investors pay more for each unit of profit.
KIRA
At $286.74 a share, the company is worth $507.8B: 81.0 times its earnings of the last four quarters.
AbbVie grew sales faster than 3 of its 3 similar companies. Its P/E is higher than 2 of 2.
Source: SEC EDGAR XBRL filings (CIK 0001551152). Data updated October 9, 2026. For information only — not investment advice. Check the original filings before relying on any figure.